Objectives

After participating in this educational activity, attendees should be able to.

1. Understand the indications for use of SGLT2 I therapy in patients with renal disease with and without DM
2. Understand impact of these agents on renal outcomes
3. Review  considerations of work-group on Implementing use of SGLT 2 inhibitors  at Baystate and in the community practices

Faculty

Barbara Ann Greco, MD
Nephrology Director
Baystate Transplant Associate Fellowship Director
Associate Clinical Professor, Tufts 

Cecilia Davis, MD
Endocrinologist
Baystate Medical Center

Leeor M Jaffe, MD
Advanced Heart Failure Cardiologist
Baystate Medical Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.